EffRx – The next Swiss IPO candidate

Christer Rosén, Chairman & CEO stated, “This is a strong supportive round of financing to assist EffRx to kick-off its first orphan drug clinical trial program as well as to start preparations for a planned IPO. We plan to shortly complement this internal financing with an external pre-IPO round to have the strongest possible position during the IPO process”.

Headquartered in Freienbach (SZ), EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that develops novel therapeutic entities including orphan indications by applying its proprietary technology platform to well characterized molecules. EffRx developments focus at improving the quality of life of patients with unmet medical needs.

The lead commercialized product, Binosto was approved by the FDA to treat osteoporosis in 2012 and is also approved in Europe and Australia. Binosto is marketed in the U.S. by Mission Pharmacal, and by local and regional distributors in other territories. The approval and commercial launch of Binosto provided EffRx an important proof-of-concept for the use of effervescent formulations and highlights a number of potential advantages over traditional therapeutic approaches.

EffRx’s lead development product, EX404, targets polycystic ovary syndrome (PCOS) in adolescents. EffRx received an orphan drug designation (ODD) from the U.S. FDA in May 2014. In Europe, EX404 will be registered as a Pediatric Use Marketing Authorization (PUMA) drug and benefit from 10 years of market exclusivity. The study of EX404 in Europe is supported by a 6 million Euro research grant from European Commission.

Additional current product development pipeline targets include diabetes and liver indications. In March 2014, EffRx and Kadmon Corporation, LLC signed a global collaboration agreement to develop formulations of certain therapies aimed at adult and pediatric orphan indications, with the goal of designing treatments that are more tolerable and ensure better treatment compliance.